GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.
The Post X-er, Post-Boomer generation considers traditional healthcare "sick care."
Shire bows out of AbbVie acquisition; CVS's PBM will charge premium for consumers who fill scripts at tobacco-selling pharmacies; Reckitt Beckinser will rebrand following demerger.
Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.
Suit alleges Purdue's OxyContin turned eastern Kentucky into "Wild West"; AbbVie-Shire $1.6B break-up fee could be tax write-off; Lilly CEO tells WSJ that 2014 has been "toughest year."
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.